ViiV Healthcare announced it has submitted an NDA to the U.S. FDA seeking approval of fostemsavir for use in combination with other antiretroviral agents in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to form a...
Emergent BioSolutions presented updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate across a series of dosing regimens....
A Kaiser Permanente Division of Research (DOR) real-world observational study has impacted new practice guidelines from the Infectious Diseases Society of America and the American Association for the Study of Liver Diseases. Published in Clinical Gastroenterology and...
Enanta Pharmaceuticals reported new data from its Phase 2a human challenge study demonstrating EDP-938 for RSV demonstrates highly statistically significant reductions in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque...
Vir Biotechnology fits the bill of an entrepreneurial operation—developing a pipeline based on deal making prowess, venture capital, and an alliance with the Bill & Melinda Gates Foundation. The San Francisco-based emerging biopharma venture now plans to go...
Healio reports that the French National Research Institute for Sustainable Development reported results from a study that children of women who used tenofovir disoproxil fumarate (TDF), to prevent transmission of hepatitis B to their children did not have lower bone...
